Holen Sie sich die Stockscreener-App
2.36
7.27%
0.16
Handel nachbörslich:
2.35
-0.010
-0.42%
Grace Therapeutics Inc Aktie (GRCE) Neueste Nachrichten
GRCE Q1 2026 Earnings: EPS Surprises to the Upside Despite No RevenueAnalyst Consensus Shift - Newser
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineGuidance Accuracy Score - Newser
Grace Therapeutics Inc. (GRCE) Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Stock DipShared Momentum Picks - Newser
GRCE Stock Chart | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - PR Newswire
GRCE Technical Analysis | Trend, Signals & Chart Patterns | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
Pomerantz LLP Investigates Claims for Grace Therapeutics Investors - Intellectia AI
Grace Therapeutics (GRCE) Gains +1.40% — Support Holds at $2.07 2026-05-20Intraday Profile - Newser
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - FinancialContent
Why Is Grace Therapeutics, Inc. (GRCE) Stock Down Today? - Meyka
Grace Therapeutics (GRCE) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.14Mature Phase - Newser
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
Grace Therapeutics (GRCE) Q1 2026 Earnings: $-0.14 EPS Surges Past $-0.29 EstimatesSocial Trade Signals - newser.com
ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics faces investigation after FDA rejects drug application, stock drops 45%. - Pluang
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - MSN
Grace Therapeutics (GRCE) Down -1.78% — How Low Could It Go? 2026-05-14Hedge Fund Inspired Picks - Newser
Number of shareholders of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Number of shareholders of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Largest borrow rate increases among liquid names - TipRanks
Grace Therapeutics, Inc. (GRCE) Eps Diluted (TTM) - Zacks Investment Research
Grace Therapeutics stock falls as FDA declines to approve brain hemorrhage drug - MSN
The organic vs inorganic growth story at Grace Therapeutics (GRCE) | Grace Therapeutics 51% EPS beat tops loss viewsDebt Refinancing - newser.com
Why Grace Therapeutics (GRCE) ability to innovate sets it apart (-1.27%) 2026-05-05Price Momentum - newser.com
GRCE stock on track for worst week in 5.5 years — what’s driving the selloff? - MSN
GRCE (Grace Therapeutics) EV-to-OCF : -0.99 (As of Apr. 30, 2026) - GuruFocus
Grace Therapeutics’ GTx-104: Novel IV Nimodipine Shows Superior Efficacy and Safety for aSAH vs. Oral Standard of Care 245 - Minichart
814,000-share position reported by AIGH, Orin Hirschman in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress - TipRanks
Grace Therapeutics (GRCE) outlines GTx-104 CRL, Phase 3 data and cash - Stock Titan
GRCE Options Volatility — NASDAQ:GRCE - TradingView
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug - Sahm
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
GRCE Maintained by TD Cowen -- Price Target Lowered to $8.00 - GuruFocus
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial - BioWorld News
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen - TipRanks
Grace hit by CRL for GTx-104, shares plunge 45% - The Pharma Letter
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum - TipRanks
Grace Therapeutics, IncFDA Does Not Reques - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):